EUVIMEDSkopri EUVIMED
Open access · CC BY-NC 4.0

Insulin‐like growth factor‐1 in cirrhosis is linked to hepatic dysfunction and fibrogenesis and predicts liver‐related mortality

Lukas Hartl iD, Michael Schwarz iD, Benedikt Simbrunner iD, Mathias Jachs iD, Peter Wolf iD, David Josef Maria Bauer iD, Bernhard Scheiner iD, Lorenz Balcar iD, Georg Semmler iD, Benedikt Silvester Hofer iD, Nina Dominik iD, Rodrig Marculescu and 3 more

Alimentary Pharmacology & Therapeutics · 2025-01 · 61 (1) · 88-98

DOI: 10.1111/apt.18289 ↗

At a glance

Journal article in Alimentary Pharmacology & Therapeutics, published online on 2024-09-21. Written by Lukas Hartl and 14 co-authors. Institution: Division of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria. Major MEDLINE topics: Insulin-Like Growth Factor I, Liver Cirrhosis. Cited 15 times so far (Crossref); 37 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: Ludwig Boltzmann Gesellschaft.

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Background and Aims We aimed to characterise insulin‐like growth factor‐1 (IGF‐1) signalling in patients with advanced chronic liver disease (ACLD).

Methods

Consecutive patients undergoing hepatic venous pressure gradient [HVPG] measurement were prospectively included. Clinical stages were defined as follows: probable ACLD (pACLD): liver stiffness ≥10 kPa and HVPG ≤5 mmHg, S0: mild PH (HVPG 6–9 mmHg), S1: clinically significant PH (CSPH), S2: CSPH with varices, S3: past variceal bleeding, S4: past/current non‐bleeding hepatic decompensation and S5: further decompensation.

Results

In total, 269 patients were included; 105 were compensated (pACLD: n = 18; S0: n = 30; S1: n = 20; S2: n = 37), and 164 were decompensated (S3: n = 11; S4: n = 89; S5: n = 64). Median levels of IGF‐1 decreased with progressive cirrhosis (from pACLD: 88.5 ng/mL to S5: 51.0 ng/mL; p < 0.001). Patients with CSPH had significantly lower IGF‐1 levels (63.5 ng/mL vs. 81.0 ng/mL; p = 0.001). IGF‐1 showed an independent negative association with body mass index (BMI; aB: −1.56; p < 0.001), enhanced liver fibrosis (ELF) test (aB: −8.43; p < 0.001), MELD (aB: −1.13; p = 0.042) and age (per 10 years; aB: −6.87; p < 0.001). IGF‐1 exhibited an excellent AUROC (0.856) for the prediction of liver‐related death at 6 months of follow‐up. Lower IGF‐1 (per 10 ng/mL) was linked to higher risk of (further) decompensation (0.90; 95% CI: 0.83–0.98; p = 0.016), acute‐on‐chronic liver failure (ACLF; asHR: 0.80; 95% CI: 0.68–0.93; p = 0.004) and liver‐related death (asHR: 0.76; 95% CI: 0.63–0.91; p = 0.004).

Conclusion

Decreased levels of IGF‐1 reflect impaired hepatic function and fibrogenesis in patients with cirrhosis, which seems particularly relevant in obesity since low IGF‐1 was independently linked to high BMI. Lower IGF‐1 in cirrhosis predicts decompensation, ACLF and liver‐related death.

Subjects

MeSH terms (MEDLINE)

Insulin-Like Growth Factor ILiver CirrhosisHumansFemaleMaleMiddle AgedAgedProspective StudiesAdultLiverBiomarkersHypertension, PortalDisease ProgressionInsulin-Like Peptides

Substances

Insulin-Like Growth Factor IIGF1 protein, humanBiomarkersInsulin-Like Peptides

Authors and institutions

  • Division of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria.
  • Vienna Hepatic Hemodynamic Lab, Division of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria.
  • Clinical Research Group MOTION, Division of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria.
  • Christian Doppler Lab for Portal Hypertension and Liver Fibrosis, Medical University of Vienna, Vienna, Austria.
  • Division of Endocrinology, Department of Medicine III, Medical University of Vienna, Vienna, Austria.
  • Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria.

ORCID profiles: Lukas Hartl, Michael Schwarz, Benedikt Simbrunner, Mathias Jachs, Peter Wolf, David Josef Maria Bauer, Bernhard Scheiner, Lorenz Balcar, Georg Semmler, Benedikt Silvester Hofer, Nina Dominik, Michael Trauner, Mattias Mandorfer, Thomas Reiberger

Funding

  • Ludwig Boltzmann Gesellschaft

Cite

APA

Hartl, L., Schwarz, M., Simbrunner, B., Jachs, M., Wolf, P., Bauer, D. J. M., Scheiner, B., Balcar, L., Semmler, G., Hofer, B. S., Dominik, N., Marculescu, R., Trauner, M., Mandorfer, M., & Reiberger, T. (2025). Insulin‐like growth factor‐1 in cirrhosis is linked to hepatic dysfunction and fibrogenesis and predicts liver‐related mortality. Alimentary Pharmacology & Therapeutics, 61(1), 88-98. https://doi.org/10.1111/apt.18289

Vancouver

Hartl L, Schwarz M, Simbrunner B, Jachs M, Wolf P, Bauer DJM, et al. Insulin‐like growth factor‐1 in cirrhosis is linked to hepatic dysfunction and fibrogenesis and predicts liver‐related mortality. Alimentary Pharmacology & Therapeutics. 2025;61(1):88-98. doi:10.1111/apt.18289

BibTeX
@article{Hartl2025,
  author = {Hartl, Lukas and Schwarz, Michael and Simbrunner, Benedikt and Jachs, Mathias and Wolf, Peter and Bauer, David Josef Maria and Scheiner, Bernhard and Balcar, Lorenz and Semmler, Georg and Hofer, Benedikt Silvester and Dominik, Nina and Marculescu, Rodrig and Trauner, Michael and Mandorfer, Mattias and Reiberger, Thomas},
  title = {Insulin‐like growth factor‐1 in cirrhosis is linked to hepatic dysfunction and fibrogenesis and predicts liver‐related mortality},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2025},
  volume = {61},
  number = {1},
  pages = {88--98},
  doi = {10.1111/apt.18289}
}
Start for free →